Recent Updates
Recently added Catalysts

Reminyl

Phase 1

Fed | Small molecule | Other |Dr. Reddy's Laboratories Ltd|Last Updated: Jun 30, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment24
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01372306Galantamine Bioequivalence Study of Dr. Reddy's Under Fed ConditionPHASE1 COMPLETED 24Oct 1, 2004Nov 1, 2004Jun 30, 2011 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioequivalence on Cmax and AUC parameters
2 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
GalantamineEXPERIMENTALGalantamine Hydrobromide Tablets of Dr. Reddy's
ReminylACTIVE_COMPARATORReminyl 4 mg tablets of Janssen Pharmaceutical Products
Interventions
NameTypeDescription
ReminylDRUGGalantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexMALE
Healthy VolunteersYes

Inclusion Criteria: Subject candidates must fulfill all of the following inclusion criteria to be eligible for participation in the studyI unless otherwise specified: * Healthy adult male volunteers, 18-55 years of age; * Weighing at least 60 kg and within 15% of their ideal weights (Table of "Des...

Unlock Eligibility Criteria